down arrow

Pediatrix Medical Group, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US58502B1061
USD
22.29
-1 (-4.29%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

22.1523.37

52 Week

11.8424.99
Valuation
Technical
Day's Volume

CASH

1.6 M

Shareholding (Mar 2025)

FII

7.03%

Held by 107 FIIs

DII

39.77%

Held by 65 DIIs

Promoter

0.00%

How big is Pediatrix Medical Group, Inc.?

22-Jun-2025

As of Jun 18, Pediatrix Medical Group, Inc. has a market capitalization of 1,152.00 million and reported net sales of 1,976.18 million with a net profit of -82.37 million over the latest four quarters. Shareholder's funds are 764.94 million, and total assets amount to 2,152.70 million.

As of Jun 18, Pediatrix Medical Group, Inc. has a market capitalization of 1,152.00 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 1,976.18 million, while the sum of net profit for the same period is -82.37 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 764.94 million and total assets amounting to 2,152.70 million.

Read More

What does Pediatrix Medical Group, Inc. do?

22-Jun-2025

Pediatrix Medical Group, Inc. provides physician services specializing in newborn, maternal-fetal, and pediatric subspecialty care. As of March 2025, it reported net sales of $458 million and a net profit of $21 million, with a market cap of $1.15 billion.

Overview:<BR>Pediatrix Medical Group, Inc. is a provider of physician services specializing in newborn, maternal-fetal, and pediatric subspecialty care within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 458 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 21 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 1,152.00 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 8.00 <BR>Debt Equity: 0.51 <BR>Return on Equity: 19.10% <BR>Price to Book: 1.46 <BR><BR>Contact Details:<BR>Address: 1301 Concord Ter, SUNRISE FL: 33323-2843 <BR>Tel: 1 954 3840175 <BR>Fax: 1 954 8389961 <BR>Website: https://www.mednax.com/

Read More

Who are in the management team of Pediatrix Medical Group, Inc.?

22-Jun-2025

As of March 2022, the management team of Pediatrix Medical Group, Inc. includes Mr. Guy Sansone (Independent Chairman), Mr. Manuel Kadre (Lead Independent Director), Dr. Roger Medel, Ms. Karey Barker, Dr. Waldemar Carlo, and Mr. Paul Gabos, all serving as directors. They are responsible for the company's strategic direction and governance.

As of March 2022, the management team of Pediatrix Medical Group, Inc. includes the following individuals:<BR><BR>- Mr. Guy Sansone, Independent Chairman of the Board<BR>- Mr. Manuel Kadre, Lead Independent Director<BR>- Dr. Roger Medel, Director<BR>- Ms. Karey Barker, Independent Director<BR>- Dr. Waldemar Carlo, Independent Director<BR>- Mr. Paul Gabos, Independent Director<BR><BR>These members play significant roles in guiding the company's strategic direction and governance.

Read More

Is Pediatrix Medical Group, Inc. technically bullish or bearish?

20-Sep-2025

As of August 29, 2025, Pediatrix Medical Group, Inc. shows a bullish trend supported by positive MACD and KST readings, despite a bearish weekly RSI and mixed signals from Dow Theory, while outperforming the S&P 500 year-to-date and over the past year.

As of 29 August 2025, the technical trend for Pediatrix Medical Group, Inc. has changed from mildly bullish to bullish. The current stance is bullish, supported by bullish MACD readings on both weekly and monthly time frames, and a bullish daily moving average. However, the weekly RSI is bearish, indicating some short-term weakness. The KST is bullish on both weekly and monthly bases, while the Bollinger Bands show a mildly bullish trend in both time frames. Dow Theory presents a mixed view with a mildly bearish weekly stance but a mildly bullish monthly outlook. <BR><BR>In terms of performance, Pediatrix has outperformed the S&P 500 year-to-date with a return of 26.45% compared to the S&P's 12.22%, and over the past year, it has returned 52.76% versus the S&P's 17.14%. However, over longer periods, the stock has underperformed significantly. Overall, the bullish trend is supported by several indicators, despite some mixed signals in the short term.

Read More

Is Pediatrix Medical Group, Inc. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, Pediatrix Medical Group, Inc. is considered very attractive and undervalued, with a P/E ratio of 8, an EV to EBITDA of 7.17, and a PEG ratio of 0.19, outperforming peers and the S&P 500 with a year-to-date return of 25.38%.

As of 17 October 2025, the valuation grade for Pediatrix Medical Group, Inc. has moved from attractive to very attractive, indicating a positive shift in its perceived value. Based on the current metrics, the company appears to be undervalued. Key ratios include a P/E ratio of 8, an EV to EBITDA of 7.17, and a PEG ratio of 0.19, all of which suggest that the stock is trading at a discount compared to its earnings growth potential.<BR><BR>In comparison to peers, Pediatrix Medical Group has a lower P/E ratio than Hims & Hers Health, Inc., which stands at 54.76, and a more favorable EV to EBITDA ratio than RadNet, Inc., which is at 26.07. This further reinforces the notion that Pediatrix is undervalued relative to its industry peers. Additionally, the company's stock has outperformed the S&P 500 across multiple periods, with a year-to-date return of 25.38% compared to the S&P 500's 13.30%, highlighting its strong performance in the market.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a growth in Net Profit of 89.32%, the company declared Very Positive results in Jun 25

  • OPERATING CASH FLOW(Y) Highest at USD 244.56 MM
  • ROCE(HY) Highest at 14.27%
  • INTEREST COVERAGE RATIO(Q) Highest at 755.9
2

With ROCE of 16.57%, it has a risky valuation with a 1.35 Enterprise value to Capital Employed

3

Market Beating Performance

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1,476 Million (Small Cap)

stock-summary
P/E

8.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.33

stock-summary
Return on Equity

18.01%

stock-summary
Price to Book

1.77

Revenue and Profits:
Net Sales:
469 Million
(Quarterly Results - Jun 2025)
Net Profit:
39 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
31.04%
0%
31.04%
6 Months
60.36%
0%
60.36%
1 Year
49.7%
0%
49.7%
2 Years
142.55%
0%
142.55%
3 Years
36.92%
0%
36.92%
4 Years
-11.79%
0%
-11.79%
5 Years
-1.11%
0%
-1.11%

Pediatrix Medical Group, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Pediatrix Medical Group Hits New 52-Week High of $22.38

Pediatrix Medical Group Hits New 52-Week High of $22.38

Pediatrix Medical Group, Inc. achieved a new 52-week high, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector with significant growth over the past year. The company boasts a market capitalization of USD 1,476 million, a favorable P/E ratio, and robust operational metrics, indicating solid financial health.

Read More
Pediatrix Medical Group Hits Day High with 24.22% Surge in Stock Price

Pediatrix Medical Group Hits Day High with 24.22% Surge in Stock Price

Pediatrix Medical Group, Inc. has shown strong performance, achieving a notable gain and reaching an intraday high. Over the past year, it has significantly outperformed the S&P 500. The company boasts a solid market capitalization, efficient management metrics, and robust financial health, indicating its strong position in the Pharmaceuticals & Biotechnology sector.

Read More
Pediatrix Medical Group Hits New 52-Week High of $21.24

Pediatrix Medical Group Hits New 52-Week High of $21.24

Pediatrix Medical Group, Inc. achieved a new 52-week high, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. With a market cap of USD 1,476 million, the company boasts impressive financial metrics, including a favorable P/E ratio, solid return on equity, and robust operating cash flow.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-9.23%
EBIT Growth (5y)
-7.17%
EBIT to Interest (avg)
3.79
Debt to EBITDA (avg)
2.77
Net Debt to Equity (avg)
0.51
Sales to Capital Employed (avg)
1.33
Tax Ratio
1.59%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
13.11%
ROE (avg)
14.52%
Valuation key factors
Factor
Value
P/E Ratio
8
Industry P/E
Price to Book Value
1.53
EV to EBIT
8.16
EV to EBITDA
7.17
EV to Capital Employed
1.35
EV to Sales
0.82
PEG Ratio
0.19
Dividend Yield
NA
ROCE (Latest)
16.57%
ROE (Latest)
19.10%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bearish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 72 Schemes (53.11%)

Foreign Institutions

Held by 107 Foreign Institutions (7.03%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 2.27% vs -8.76% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 89.86% vs -32.13% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "468.80",
          "val2": "458.40",
          "chgp": "2.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "69.00",
          "val2": "44.00",
          "chgp": "56.82%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "9.10",
          "val2": "9.20",
          "chgp": "-1.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.80",
          "val2": "-6.60",
          "chgp": "42.42%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "39.30",
          "val2": "20.70",
          "chgp": "89.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "135.90%",
          "val2": "84.40%",
          "chgp": "5.15%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.92% vs 1.15% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -64.07% vs -196.49% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,012.90",
          "val2": "1,994.60",
          "chgp": "0.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "215.90",
          "val2": "194.00",
          "chgp": "11.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "40.70",
          "val2": "42.10",
          "chgp": "-3.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-242.70",
          "val2": "-170.50",
          "chgp": "-42.35%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-99.10",
          "val2": "-60.40",
          "chgp": "-64.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "91.30%",
          "val2": "79.10%",
          "chgp": "1.22%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
468.80
458.40
2.27%
Operating Profit (PBDIT) excl Other Income
69.00
44.00
56.82%
Interest
9.10
9.20
-1.09%
Exceptional Items
-3.80
-6.60
42.42%
Consolidate Net Profit
39.30
20.70
89.86%
Operating Profit Margin (Excl OI)
135.90%
84.40%
5.15%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 2.27% vs -8.76% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 89.86% vs -32.13% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
2,012.90
1,994.60
0.92%
Operating Profit (PBDIT) excl Other Income
215.90
194.00
11.29%
Interest
40.70
42.10
-3.33%
Exceptional Items
-242.70
-170.50
-42.35%
Consolidate Net Profit
-99.10
-60.40
-64.07%
Operating Profit Margin (Excl OI)
91.30%
79.10%
1.22%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.92% vs 1.15% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -64.07% vs -196.49% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Pediatrix Medical Group, Inc. stock-summary
stock-summary
Pediatrix Medical Group, Inc.
Pharmaceuticals & Biotechnology
MEDNAX, Inc is a provider of physician services, including newborn, maternal-fetal, pediatric cardiology and other pediatric subspecialty care. The Company's national network consist of physicians, including over physicians providing neonatal clinical care, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. It also has affiliated physicians providing maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice. Its network also included other pediatric subspecialists, physicians providing pediatric intensive care, pediatric cardiology care, hospital-based pediatric care, pediatric surgical care, pediatric ear, nose and throat and pediatric ophthalmology services.
Company Coordinates stock-summary
Company Details
1301 Concord Ter , SUNRISE FL : 33323-2843
stock-summary
Tel: 1 954 38401751 954 3840175
stock-summary
https://www.mednax.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."